New cocktail of drugs aims to tackle multiple myeloma early

NCT ID NCT05695508

Recruiting now Disease control Sponsor: University of Heidelberg Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing several new drug combinations, including teclistamab, talquetamab, and JNJ-79635322, in 160 people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if these combinations are safe and more effective than current treatments at controlling the disease before and after transplant. Participants will receive different drug regimens to find the best approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teclistamab, talquetamab, JNJ-79635322, daratumumab, lenalidomide, bortezomib, and dexamethasone
What this could lead to: If successful, this could lead to more effective and safer treatment combinations for newly diagnosed multiple myeloma, potentially improving remission rates and reducing the need for intensive chemotherapy and stem cell transplant.
What could go wrong: This is an early-phase (Phase 2) trial with a small number of participants (160), so results may not apply to all patients. The drug combinations may cause significant side effects, and it's uncertain if they will outperform current standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Asklepios Clinic Hamburg Altona
RECRUITING

Hamburg, 22763, Germany
Charité University Medicin Berlin
RECRUITING

Berlin, 12203, Germany
Clinic Chemnitz gGmbH
RECRUITING

Chemnitz, 09113, Germany
Hamburg University Clinic Eppendorf
RECRUITING

Hamburg, 20246, Germany
Technical University Munich
RECRUITING

Munich, 81675, Germany
University Clinic Düsseldorf
RECRUITING

Düsseldorf, 40225, Germany
University Clinic Freiburg
RECRUITING

Freiburg im Breisgau, 79106, Germany
University Clinic Schleswig-Holstein Campus Kiel
RECRUITING

Kiel, 24105, Germany
University Clinic Technical University Dresden
RECRUITING

Dresden, 01307, Germany
University Hospital Heidelberg
RECRUITING

Heidelberg, 69120, Germany
University Würzburg
RECRUITING

Würzburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.